Ireland caps medical cannabis flower at 230 milligrams of THC per gram and 5 grams per pack. For many high-potency Canadian cultivars, that one clause in S.I. No. 262 of 2019 settles the question before a permit form is filed.
Exporting cannabis to Ireland from Canada is possible in 2026, with conditions most first-time exporters can't meet yet. Irish patients can only receive flower through the Medical Cannabis Access Programme (MCAP) or a named-patient ministerial licence. To join MCAP, your flower must already be authorised and supplied to patients in another EU Member State, test at or below 23% THC, and ship in English-labelled packs of 5 grams or less.
For a Health Canada Licensed Producer, the order of entry matters more than the paperwork. Ireland only opens once your flower is already reaching patients elsewhere in the EU.
How Ireland's Medical Cannabis Access Programme works
MCAP runs under the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019. The Minister for Health signed them on 26 June 2019 and set the program up as a five-year pilot. It exists for cannabis products of standardised quality that don't hold a marketing authorisation, so licensed medicines sit outside it.
Only a medical consultant can prescribe under MCAP, and only for the three indications in Schedule 2 of the regulations:
- Spasticity associated with multiple sclerosis that has resisted standard therapies
- Intractable nausea and vomiting associated with chemotherapy
- Severe, refractory epilepsy that hasn't responded to standard anticonvulsants
Schedule 1 is the product list
No product can be prescribed under MCAP until the Minister adds it to Schedule 1 by statutory instrument. The supplier applies to the Health Products Regulatory Authority (HPRA), which checks the evidence against the legal definition and advises the Minister. The HPRA only considers finished products that need no further processing.
The current schedule, S.I. No. 229 of 2025, lists 11 products. Two are dried flower: Oleo Bedrocan at 22% THC and Oleo Bedrobinol at 13.5% THC. Both come from the Bureau voor Medicinale Cannabis in the Netherlands, and both were already supplied to Dutch patients before Ireland listed them.
The ministerial licence route
Outside MCAP, the Minister can issue a licence under section 14 of the Misuse of Drugs Act 1977 for a specific product and a named patient. The MCAP prescribing rules in Part 2 of the 2019 regulations don't apply to those licences. Volumes are patient by patient, so this route can't anchor a supply forecast.
A review is under way
On 30 September 2026, Minister for Health Jennifer Carroll MacNeill told the Dáil that a Review of Access to Cannabis for Medical Use is examining how MCAP and the ministerial licence scheme operate, and whether to add conditions. Her answer gave no timeline and no change to the product criteria. Until the review reports, plan against the 2019 definition as written. It's the only test an HPRA assessor can apply.
The six MCAP tests your flower must pass
The 2019 regulations define a "specified controlled drug" through a list of conditions, sub-paragraphs (a) to (g). The last one is simply being listed in Schedule 1. The other six are the tests your flower has to pass first. Call it the MCAP six-test screen.
| Test | What S.I. 262 of 2019 requires | Where Canadian LPs stall |
|---|---|---|
| 1. Source material | Made from dried, ground or powdered cannabis flower | Rarely an issue for flower suppliers |
| 2. No marketing authorisation | Not an authorised medicinal product | Not an issue for unlicensed flower |
| 3. Potency and pack size | Max 230 mg THC per gram, max 5 g per pack | High-THC export cultivars exceed the cap |
| 4. EU authorisation | Permitted for medical supply in another Member State | No EU market access yet |
| 5. Current EU supply | Currently supplied to patients in that Member State | Authorised but not yet shipping |
| 6. Labelling | English packaging and labels per HPRA guidance | Bulk formats need patient-ready redesign |
The potency ceiling
Test three removes many premium cultivars before any paperwork starts. Our own Ice Cream Cake tests at 30.3% THC, well above Ireland's 23% ceiling. If your portfolio leans high-potency, Ireland needs a different cultivar, one that stays under the cap across every batch with room for lab-to-lab variance.
Ask the HPRA early how it reads the figure for flower labelled as total THC. The answer changes which cultivars qualify, and our guide to THCA vs THC potency labelling explains why the two numbers diverge.
The EU supply test
Tests four and five are the real gate. Ireland doesn't judge Canadian flower on its own merits first. It asks whether another EU regulator has already let the product reach patients, and whether patients there are receiving it now.
A Canadian LP with no EU footprint can't qualify yet, whatever its documentation looks like. For most exporters, the German medical cannabis market is the obvious first step, and the two listed flowers show the Dutch route works too.
Pack size and labelling
The 5 g limit means Ireland wants finished, patient-ready units. If your EU partner imports bulk and repacks it, the partner's pack is the product the HPRA assesses. Agree the English label set and pack format with that partner before anyone files, especially under a private-label cannabis supply arrangement. One failed test ends the application until it's fixed.
Import licences and the permit chain from Canada to Ireland
A Schedule 1 listing lets consultants prescribe your product. It doesn't move a single gram. Every shipment still runs through the two-permit chain that the Single Convention on Narcotic Drugs sets up between exporting and importing states.
The Canada to Ireland permit path: 5 steps
- Your Irish partner holds an HPRA controlled drugs licence to possess, supply or import Schedule 2 products. MCAP products sit in Schedule 2 of the Misuse of Drugs Regulations 2017.
- The partner applies to the HPRA for an import licence covering the specific consignment.
- You apply for a Health Canada export permit under the Cannabis Regulations, supported by the Irish import licence. Our walkthrough of the Health Canada export permit process covers the forms.
- The quantity counts against Ireland's annual cannabis estimate with the INCB, so large first orders need checking early.
- The shipment clears into Ireland and your partner holds and distributes it under its HPRA licence.
Shipments slow down on sequence. The export permit needs the Irish import licence in hand, and that licence covers one consignment. If your partner applies late, your released batch sits in the vault while its shelf-life clock keeps running.
MCAP doesn't provide for domestic cultivation, so every flower prescribed under it is imported. Build the Irish import licence date into your production schedule and release the batch against it.
Where Ireland fits in your EU export plan
Ireland is a small, tightly controlled channel. Eleven products are listed, two of them flower, and patients reach them only through three indications and a consultant's prescription. The HSE meets the cost of approved MCAP products through its reimbursement schemes, which supports steady repeat demand for whoever is already listed.
Ireland isn't a first export market for a Canadian LP. It's a second step after Germany or the Netherlands, and only for cultivars under 23% THC.
The LPs that should look now share three traits:
- A cultivar already supplied to patients in an EU Member State
- Batch data that holds below 230 mg THC per gram
- An EU partner willing to produce English, 5 g patient packs
If you're missing the first trait, compare EU import markets by country and pick your entry market before Ireland. Applying early gains nothing when test four can't be met.
AlphaLeaf is a Health Canada Licensed Producer in Montreal, growing indoor, hand-trimmed flower from refined genetics. We hold export authorisation under the Cannabis Act and back each batch with ISO/IEC 17025 accredited testing and full traceability, the record set an Irish importer and its EU supply partner will ask to see.
If your EU plan ends in Dublin, talk to our export team about cultivar selection. Start with the cultivar. The permits come later.
Frequently Asked Questions
Can a Canadian Licensed Producer export cannabis flower to Ireland?
Yes, but only for products listed in Schedule 1 of S.I. No. 262 of 2019 or supplied under a ministerial licence. To be listed, the flower must already be authorised and currently supplied to patients in another EU Member State.
What is the THC limit for dried flower under Ireland's Medical Cannabis Access Programme?
Dried flower can contain no more than 230 milligrams of THC per gram, roughly 23%. Each pack can hold no more than 5 grams.
Who approves cannabis products for the Medical Cannabis Access Programme?
The supplier applies to the Health Products Regulatory Authority, which assesses the product against the legal criteria and advises the Minister for Health. The Minister then adds approved products to Schedule 1 by statutory instrument.
Which dried flower products are approved in Ireland?
Under S.I. No. 229 of 2025, two dried flower products are listed: Oleo Bedrocan at 22% THC and Oleo Bedrobinol at 13.5% THC. Both are supplied through the Bureau voor Medicinale Cannabis in the Netherlands.
What licences are needed to import medical cannabis into Ireland?
The Irish importer needs an HPRA controlled drugs licence for Schedule 2 products and an import licence for each consignment. The Canadian exporter needs a Health Canada export permit for each shipment.
Is Ireland expanding its medical cannabis program in 2026?
A Review of Access to Cannabis for Medical Use is examining MCAP, the ministerial licence scheme and possible new conditions, according to the Minister for Health in September 2026. No timeline or change to the product criteria has been announced.
